TFPI2 and neoplasm: TFPI-2 is downregulated in aggressive cancers, such as breast cancer and glioma, and recombinant therapy or overexpression of this protein reduces tumor cell migration and invasion (Fayard et al., 2009; Lavergne et al., 2013; Wang et al., 2018).